Performance of Hemochron ACT-LR and ACT+ Test Cuvettes in Monitoring Low to Moderate Heparin Concentrations: An In Vitro Study

According to the manufacturer, the Hemochron ACT-LR cuvette is designated for heparin concentrations of 0 to 2.5 IU/mL, while the optimal concentration range for the ACT+ cartridge is 1 to 6 IU/mL. We hypothesized that at low to moderate heparin concentrations, the ACT-LR is more reliable than the A...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiothoracic and vascular anesthesia 2024-12
Hauptverfasser: Moilanen, Janne, Pada, Marika, Ohtonen, Pasi, Kaakinen, Timo, Pokela, Matti, Savolainen, Eeva-Riitta, Erkinaro, Tiina
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Journal of cardiothoracic and vascular anesthesia
container_volume
creator Moilanen, Janne
Pada, Marika
Ohtonen, Pasi
Kaakinen, Timo
Pokela, Matti
Savolainen, Eeva-Riitta
Erkinaro, Tiina
description According to the manufacturer, the Hemochron ACT-LR cuvette is designated for heparin concentrations of 0 to 2.5 IU/mL, while the optimal concentration range for the ACT+ cartridge is 1 to 6 IU/mL. We hypothesized that at low to moderate heparin concentrations, the ACT-LR is more reliable than the ACT+. An in vitro study. A tertiary care university hospital. Twenty healthy adult volunteers. Donor blood samples were spiked with unfractionated heparin to concentrations of 0, 0.5, 1.0, 1.5, 2.0, and 2.5 IU/mL. From each concentration, 3 measurements were made with each test cassette using 3 different Hemochron Signature Elite devices, for a total of 720 ACT tests. The Bland-Altman method and intraclass correlation coefficients were used to analyze the data. All 360 ACT+ tests yielded a result. Of 360, 38 (11%) ACT-LR tests ran above the upper measurement range; of these, 36 were from the 120 measurements at heparin concentrations ≥2.0 IU/mL. The bias between all ACT-LR and ACT+ measurements ​​was 52 (95% CI, 48-56) celite seconds, and the limits of agreement were wide. Based on the intraclass correlation coefficients, the reliability of ACT+ was better than or equal to that of ACT-LR. The performance of ACT+ is equal to that of ACT-LR up to a concentration of 0.5 IU/mL, above which ACT+ is superior to ACT-LR, questioning the rationale for a specific low-range test. However, there is a significant bias between ACT-LR and ACT+ measurements that needs to be considered if switching from one test to the other.
doi_str_mv 10.1053/j.jvca.2024.12.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3147972589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S105307702400939X</els_id><sourcerecordid>3147972589</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1523-ba1787bd0fe523d0a2fc870c712a6ab2580e34a8c499f9c83b376e288dca47213</originalsourceid><addsrcrecordid>eNp9kE2P0zAQhi0EYpeFP8AB-YiEEvyR1AniUkXArlQEgsLVcuwJuGrsru0U7YXfzlRdOHLyeOaZR5qXkOec1Zy18vWu3h2tqQUTTc1FzRh_QC55K0XVNUI8xBqpiinFLsiTnHcI8LZVj8mF7BVbrXp5SX5_hjTFNJtggcaJXsMc7c8UA10P22rzhZrgTuUruoVc6LAcoRTI1Af6MQZfYvLhB93EX7RE7DhIpgBaDgYHdIioDQV7Pob8hq4DvQn0uy8p0q9lcXdPyaPJ7DM8u3-vyLf377bDdbX59OFmWG8qy1shq9Fw1anRsQnw65gRk-0Us4oLszKjaDsGsjGdbfp-6m0nR6lWILrOWdMoweUVeXn2HlK8XfASPftsYb83AeKSteSN6hV6ekTFGbUp5pxg0ofkZ5PuNGf6lKje6VPu-pS75kJjrLj04t6_jDO4fyt_g0bg7RkAvPLoIelsPWA6ziewRbvo_-f_Azv7kx8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3147972589</pqid></control><display><type>article</type><title>Performance of Hemochron ACT-LR and ACT+ Test Cuvettes in Monitoring Low to Moderate Heparin Concentrations: An In Vitro Study</title><source>Elsevier ScienceDirect Journals</source><creator>Moilanen, Janne ; Pada, Marika ; Ohtonen, Pasi ; Kaakinen, Timo ; Pokela, Matti ; Savolainen, Eeva-Riitta ; Erkinaro, Tiina</creator><creatorcontrib>Moilanen, Janne ; Pada, Marika ; Ohtonen, Pasi ; Kaakinen, Timo ; Pokela, Matti ; Savolainen, Eeva-Riitta ; Erkinaro, Tiina</creatorcontrib><description>According to the manufacturer, the Hemochron ACT-LR cuvette is designated for heparin concentrations of 0 to 2.5 IU/mL, while the optimal concentration range for the ACT+ cartridge is 1 to 6 IU/mL. We hypothesized that at low to moderate heparin concentrations, the ACT-LR is more reliable than the ACT+. An in vitro study. A tertiary care university hospital. Twenty healthy adult volunteers. Donor blood samples were spiked with unfractionated heparin to concentrations of 0, 0.5, 1.0, 1.5, 2.0, and 2.5 IU/mL. From each concentration, 3 measurements were made with each test cassette using 3 different Hemochron Signature Elite devices, for a total of 720 ACT tests. The Bland-Altman method and intraclass correlation coefficients were used to analyze the data. All 360 ACT+ tests yielded a result. Of 360, 38 (11%) ACT-LR tests ran above the upper measurement range; of these, 36 were from the 120 measurements at heparin concentrations ≥2.0 IU/mL. The bias between all ACT-LR and ACT+ measurements ​​was 52 (95% CI, 48-56) celite seconds, and the limits of agreement were wide. Based on the intraclass correlation coefficients, the reliability of ACT+ was better than or equal to that of ACT-LR. The performance of ACT+ is equal to that of ACT-LR up to a concentration of 0.5 IU/mL, above which ACT+ is superior to ACT-LR, questioning the rationale for a specific low-range test. However, there is a significant bias between ACT-LR and ACT+ measurements that needs to be considered if switching from one test to the other.</description><identifier>ISSN: 1053-0770</identifier><identifier>ISSN: 1532-8422</identifier><identifier>EISSN: 1532-8422</identifier><identifier>DOI: 10.1053/j.jvca.2024.12.001</identifier><identifier>PMID: 39706693</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Activated Clotting Time ; Hemochron Signature Elite ; Unfractionated heparin</subject><ispartof>Journal of cardiothoracic and vascular anesthesia, 2024-12</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1523-ba1787bd0fe523d0a2fc870c712a6ab2580e34a8c499f9c83b376e288dca47213</cites><orcidid>0009-0006-6449-4734</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S105307702400939X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39706693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moilanen, Janne</creatorcontrib><creatorcontrib>Pada, Marika</creatorcontrib><creatorcontrib>Ohtonen, Pasi</creatorcontrib><creatorcontrib>Kaakinen, Timo</creatorcontrib><creatorcontrib>Pokela, Matti</creatorcontrib><creatorcontrib>Savolainen, Eeva-Riitta</creatorcontrib><creatorcontrib>Erkinaro, Tiina</creatorcontrib><title>Performance of Hemochron ACT-LR and ACT+ Test Cuvettes in Monitoring Low to Moderate Heparin Concentrations: An In Vitro Study</title><title>Journal of cardiothoracic and vascular anesthesia</title><addtitle>J Cardiothorac Vasc Anesth</addtitle><description>According to the manufacturer, the Hemochron ACT-LR cuvette is designated for heparin concentrations of 0 to 2.5 IU/mL, while the optimal concentration range for the ACT+ cartridge is 1 to 6 IU/mL. We hypothesized that at low to moderate heparin concentrations, the ACT-LR is more reliable than the ACT+. An in vitro study. A tertiary care university hospital. Twenty healthy adult volunteers. Donor blood samples were spiked with unfractionated heparin to concentrations of 0, 0.5, 1.0, 1.5, 2.0, and 2.5 IU/mL. From each concentration, 3 measurements were made with each test cassette using 3 different Hemochron Signature Elite devices, for a total of 720 ACT tests. The Bland-Altman method and intraclass correlation coefficients were used to analyze the data. All 360 ACT+ tests yielded a result. Of 360, 38 (11%) ACT-LR tests ran above the upper measurement range; of these, 36 were from the 120 measurements at heparin concentrations ≥2.0 IU/mL. The bias between all ACT-LR and ACT+ measurements ​​was 52 (95% CI, 48-56) celite seconds, and the limits of agreement were wide. Based on the intraclass correlation coefficients, the reliability of ACT+ was better than or equal to that of ACT-LR. The performance of ACT+ is equal to that of ACT-LR up to a concentration of 0.5 IU/mL, above which ACT+ is superior to ACT-LR, questioning the rationale for a specific low-range test. However, there is a significant bias between ACT-LR and ACT+ measurements that needs to be considered if switching from one test to the other.</description><subject>Activated Clotting Time</subject><subject>Hemochron Signature Elite</subject><subject>Unfractionated heparin</subject><issn>1053-0770</issn><issn>1532-8422</issn><issn>1532-8422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kE2P0zAQhi0EYpeFP8AB-YiEEvyR1AniUkXArlQEgsLVcuwJuGrsru0U7YXfzlRdOHLyeOaZR5qXkOec1Zy18vWu3h2tqQUTTc1FzRh_QC55K0XVNUI8xBqpiinFLsiTnHcI8LZVj8mF7BVbrXp5SX5_hjTFNJtggcaJXsMc7c8UA10P22rzhZrgTuUruoVc6LAcoRTI1Af6MQZfYvLhB93EX7RE7DhIpgBaDgYHdIioDQV7Pob8hq4DvQn0uy8p0q9lcXdPyaPJ7DM8u3-vyLf377bDdbX59OFmWG8qy1shq9Fw1anRsQnw65gRk-0Us4oLszKjaDsGsjGdbfp-6m0nR6lWILrOWdMoweUVeXn2HlK8XfASPftsYb83AeKSteSN6hV6ekTFGbUp5pxg0ofkZ5PuNGf6lKje6VPu-pS75kJjrLj04t6_jDO4fyt_g0bg7RkAvPLoIelsPWA6ziewRbvo_-f_Azv7kx8</recordid><startdate>20241204</startdate><enddate>20241204</enddate><creator>Moilanen, Janne</creator><creator>Pada, Marika</creator><creator>Ohtonen, Pasi</creator><creator>Kaakinen, Timo</creator><creator>Pokela, Matti</creator><creator>Savolainen, Eeva-Riitta</creator><creator>Erkinaro, Tiina</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0006-6449-4734</orcidid></search><sort><creationdate>20241204</creationdate><title>Performance of Hemochron ACT-LR and ACT+ Test Cuvettes in Monitoring Low to Moderate Heparin Concentrations: An In Vitro Study</title><author>Moilanen, Janne ; Pada, Marika ; Ohtonen, Pasi ; Kaakinen, Timo ; Pokela, Matti ; Savolainen, Eeva-Riitta ; Erkinaro, Tiina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1523-ba1787bd0fe523d0a2fc870c712a6ab2580e34a8c499f9c83b376e288dca47213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Activated Clotting Time</topic><topic>Hemochron Signature Elite</topic><topic>Unfractionated heparin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moilanen, Janne</creatorcontrib><creatorcontrib>Pada, Marika</creatorcontrib><creatorcontrib>Ohtonen, Pasi</creatorcontrib><creatorcontrib>Kaakinen, Timo</creatorcontrib><creatorcontrib>Pokela, Matti</creatorcontrib><creatorcontrib>Savolainen, Eeva-Riitta</creatorcontrib><creatorcontrib>Erkinaro, Tiina</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiothoracic and vascular anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moilanen, Janne</au><au>Pada, Marika</au><au>Ohtonen, Pasi</au><au>Kaakinen, Timo</au><au>Pokela, Matti</au><au>Savolainen, Eeva-Riitta</au><au>Erkinaro, Tiina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Performance of Hemochron ACT-LR and ACT+ Test Cuvettes in Monitoring Low to Moderate Heparin Concentrations: An In Vitro Study</atitle><jtitle>Journal of cardiothoracic and vascular anesthesia</jtitle><addtitle>J Cardiothorac Vasc Anesth</addtitle><date>2024-12-04</date><risdate>2024</risdate><issn>1053-0770</issn><issn>1532-8422</issn><eissn>1532-8422</eissn><abstract>According to the manufacturer, the Hemochron ACT-LR cuvette is designated for heparin concentrations of 0 to 2.5 IU/mL, while the optimal concentration range for the ACT+ cartridge is 1 to 6 IU/mL. We hypothesized that at low to moderate heparin concentrations, the ACT-LR is more reliable than the ACT+. An in vitro study. A tertiary care university hospital. Twenty healthy adult volunteers. Donor blood samples were spiked with unfractionated heparin to concentrations of 0, 0.5, 1.0, 1.5, 2.0, and 2.5 IU/mL. From each concentration, 3 measurements were made with each test cassette using 3 different Hemochron Signature Elite devices, for a total of 720 ACT tests. The Bland-Altman method and intraclass correlation coefficients were used to analyze the data. All 360 ACT+ tests yielded a result. Of 360, 38 (11%) ACT-LR tests ran above the upper measurement range; of these, 36 were from the 120 measurements at heparin concentrations ≥2.0 IU/mL. The bias between all ACT-LR and ACT+ measurements ​​was 52 (95% CI, 48-56) celite seconds, and the limits of agreement were wide. Based on the intraclass correlation coefficients, the reliability of ACT+ was better than or equal to that of ACT-LR. The performance of ACT+ is equal to that of ACT-LR up to a concentration of 0.5 IU/mL, above which ACT+ is superior to ACT-LR, questioning the rationale for a specific low-range test. However, there is a significant bias between ACT-LR and ACT+ measurements that needs to be considered if switching from one test to the other.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39706693</pmid><doi>10.1053/j.jvca.2024.12.001</doi><orcidid>https://orcid.org/0009-0006-6449-4734</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1053-0770
ispartof Journal of cardiothoracic and vascular anesthesia, 2024-12
issn 1053-0770
1532-8422
1532-8422
language eng
recordid cdi_proquest_miscellaneous_3147972589
source Elsevier ScienceDirect Journals
subjects Activated Clotting Time
Hemochron Signature Elite
Unfractionated heparin
title Performance of Hemochron ACT-LR and ACT+ Test Cuvettes in Monitoring Low to Moderate Heparin Concentrations: An In Vitro Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T08%3A09%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Performance%20of%20Hemochron%20ACT-LR%20and%20ACT+%20Test%20Cuvettes%20in%20Monitoring%20Low%20to%20Moderate%20Heparin%20Concentrations:%20An%20In%20Vitro%20Study&rft.jtitle=Journal%20of%20cardiothoracic%20and%20vascular%20anesthesia&rft.au=Moilanen,%20Janne&rft.date=2024-12-04&rft.issn=1053-0770&rft.eissn=1532-8422&rft_id=info:doi/10.1053/j.jvca.2024.12.001&rft_dat=%3Cproquest_cross%3E3147972589%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3147972589&rft_id=info:pmid/39706693&rft_els_id=S105307702400939X&rfr_iscdi=true